Gilead plans to halt free access to an HIV drug, worrying patient advocates
Gilead Sciences will no longer provide four HIV medicines for free as part of a patient assistance program starting at the end of January.
Related Articles
From Lab to Life: What AI Tells Us About ‘Long Covid’
In this episode of “From Lab to Life,” Keyla Sá, a researcher at Yale University School of Medicine, discusses her work tracking how long COVID…
A new biotech licensing Chinese drugs with a unique approach gets high-profile backing
Expedition Therapeutics, a new startup hoping to source the best therapies being developed in China and bring them stateside, has secured high-profile backing.
A new biotech licensing Chinese drugs with a unique approach gets high-profile backing
Expedition Therapeutics, a new startup hoping to source the best therapies being developed in China and bring them stateside, has secured high-profile backing.
EU health regulator clears use of AI tool in fatty liver disease trials
A European Medicines Agency committee, on Thursday, accepted the use of an artificial intelligence (AI) tool called AIM-NASH in clinical trials to help identify the…
Gene therapies and CRISPR drugs slowed by ‘irrational pessimism,’ say scientists forging new paths
Gene therapy pioneer Jim Wilson and researcher Kiran Musunuru are using contrasting approaches to overcome “irrational pessimism” clouding the field. #STATBreakthrough
Why don’t we remember being a baby? New study provides clues
Though we learn so much during our first years of life, we can’t, as adults, remember specific events from that time. Researchers have long believed…
Former CDC director Tom Frieden shares warning for RFK Jr. on measles outbreak
Wavering on vaccines and slashing public health spending could allow the Texas outbreak to turn into a disaster, Frieden says at #STATBreakthrough.
Nernst equilibrium, rectification, and saturation: Insights into ion channel behavior
The dissipation of electrochemical gradients through ion channels plays a central role in biology. Herein we use voltage-responsive kinetic models of ion channels to explore…
Sanofi Expands Immunology Prospects, Acquiring Novel Bispecific Drug in $600M Deal – MedCity News
Sanofi is building on its immunology ambitions by acquiring an early clinical Dren Bio drug candidate that offers a potential first-in-class approach to autoimmune disorders…
Tapping the potential of GLP-1 drugs requires integrated care and overcoming inequities, executives say
At STAT’s Breakthrough Summit East, the CEOs of Ro and Included Health said the the U.S. health care system poses obstacles to maximizing the potential…